• 1. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 2. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Research Briefing on 4,6-Dichloro-3-(1H)indazole Carboxylic Acid (CAS: 885520-64-9)

4,6-Dichloro-3-(1H)indazole Carboxylic Acid (CAS: 885520-64-9) is a key intermediate compound in the synthesis of various biologically active molecules, particularly in the development of kinase inhibitors and other therapeutic agents. Recent studies have highlighted its significance in medicinal chemistry due to its versatile chemical structure and potential applications in drug discovery. This research briefing aims to provide an overview of the latest advancements related to this compound, focusing on its synthesis, biological activities, and potential therapeutic applications.

Recent literature has emphasized the role of 4,6-Dichloro-3-(1H)indazole Carboxylic Acid as a building block for the development of novel kinase inhibitors. Kinases are critical targets in cancer therapy, and the indazole scaffold has been widely explored for its ability to modulate kinase activity. Studies have demonstrated that derivatives of this compound exhibit potent inhibitory effects against specific kinases, such as JAK2 and FLT3, which are implicated in various malignancies. These findings underscore the compound's potential as a starting point for the design of next-generation anticancer agents.

In addition to its applications in oncology, 4,6-Dichloro-3-(1H)indazole Carboxylic Acid has also been investigated for its role in inflammatory and autoimmune diseases. Recent research has shown that indazole-based compounds can modulate immune responses by targeting key signaling pathways, such as the NF-κB and MAPK pathways. This has led to increased interest in the compound as a potential therapeutic agent for conditions like rheumatoid arthritis and inflammatory bowel disease. Further studies are needed to elucidate its mechanism of action and optimize its pharmacological properties.

The synthesis of 4,6-Dichloro-3-(1H)indazole Carboxylic Acid has been a subject of recent optimization efforts. Novel synthetic routes have been developed to improve yield and purity, making the compound more accessible for research and development. For instance, a recent study reported a streamlined synthesis method using palladium-catalyzed cross-coupling reactions, which significantly reduced the number of steps and improved overall efficiency. Such advancements are expected to facilitate the broader use of this compound in drug discovery programs.

Despite its promising applications, challenges remain in the development of 4,6-Dichloro-3-(1H)indazole Carboxylic Acid derivatives. Issues such as solubility, bioavailability, and off-target effects need to be addressed to fully realize its therapeutic potential. Ongoing research is focused on structural modifications to enhance these properties while maintaining the compound's biological activity. Collaborative efforts between academic and industrial researchers are crucial to overcoming these hurdles and advancing the compound toward clinical applications.

In conclusion, 4,6-Dichloro-3-(1H)indazole Carboxylic Acid (CAS: 885520-64-9) represents a valuable scaffold in medicinal chemistry, with diverse applications in oncology and immunology. Recent studies have expanded our understanding of its biological activities and synthetic accessibility, paving the way for future drug development. Continued research and innovation will be essential to harness its full potential and translate these findings into clinically relevant therapies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)